Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by TCR2 Therapeutics
TCR² Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 03, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
March 23, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors
March 06, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023
February 08, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Announces Pipeline Priorities for 2023
January 05, 2023
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference
November 23, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 08, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Presents Preclinical Data on Functional Activity of Gavo-cel at the Society for Immunotherapy of Cancer
November 07, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 01, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
gavo-cel Continues to Demonstrate Clinical Benefit in Solid Tumors with Additional RECIST Reponses in Ovarian Cancer and Mesothelioma
September 28, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors
September 27, 2022
From
TCR2 Therapeutics
Via
GlobeNewswire
Tickers
TCRR
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
